# Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.

> PubMed lists PMID 41524543 in Expert review of pharmacoeconomics & outcomes research as Journal Article, Observational Study, with publication-date metadata of 2026-01-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41524543-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41524543-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41524543-semaglutide-v1.json
- Content SHA-256: `3d364fd70d7978cdfcbaaddf99324c0a8f9e9aff950d8c485269f8952f646321`

## Claims and source pins

### Headline

Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States. ([`pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0`](#source-pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0))

### Summary

PubMed lists PMID 41524543 in Expert review of pharmacoeconomics & outcomes research as Journal Article, Observational Study, with publication-date metadata of 2026-01-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0`](#source-pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0))

### Paragraph 1

PubMed lists PMID 41524543 in Expert review of pharmacoeconomics & outcomes research as Journal Article, Observational Study, with publication-date metadata of 2026-01-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0`](#source-pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0`](#source-pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0))

## Sources

<a id="source-pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0"></a>
- **Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States. · retained source version 1:2026-06-26:current:bbb71d7f68d0069e0fc86a1ce914b34739ea949e7302b1548d9f6b19bfc5987e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41524543/) (`pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41524543-semaglutide-v1.json SHA-256: 3d364fd70d7978cdfcbaaddf99324c0a8f9e9aff950d8c485269f8952f646321.